RT Journal Article
SR Electronic
T1 PARP expression in germ cell tumours
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 607
OP 612
DO 10.1136/jclinpath-2012-201088
VO 66
IS 7
A1 Mego, Michal
A1 Cierna, Zuzana
A1 Svetlovska, Daniela
A1 Macak, Dusan
A1 Machalekova, Katarina
A1 Miskovska, Viera
A1 Chovanec, Michal
A1 Usakova, Vanda
A1 Obertova, Jana
A1 Babal, Pavel
A1 Mardiak, Jozef
YR 2013
UL http://jcp.bmj.com/content/66/7/607.abstract
AB Background Poly(ADP-ribose)polymerase (PARP) inhibitors represent a new class of promising drugs in anticancer therapy. Aims To evaluate PARP expression in testicular germ cell tumours (GCTs) and to correlate expression patterns with clinicopathological variables. Methods In this translational study, tumour specimens from 124 patients with GCTs (114 patients with testicular primary tumours and 10 with extragonadal GCTs) were identified. PARP expression was detected by immunohistochemistry using monoclonal antibodies, scored by the multiplicative quickscore (QS) method and compared to PARP expression in normal testicular tissue. Results We observed higher expression of PARP in testicular tumours compared to normal testicular tissue (mean QS=10.04 vs 3.31, p<0.0000001). Mean QS±SD for each histological subtype was as follows: intratubular germ cell neoplasia unclassified (IGCNU)=18.00±0.00, embryonal carcinoma=9.62±5.64, seminoma=9.74±6.51, yolk sac tumour=7.8±7.20, teratoma=5.87±5.34, and choriocarcinoma=4.50±8.33. The PARP overexpression (QS>9) was most often detected in IGCNU (100% of specimen with PARP overexpression), seminona (52.6%), embryonal carcinoma (47.0%), yolk sac tumour (33.3%), teratoma (26.7%) and choriocarcinoma (25.0%), compared to 1.9% of normal testicular tissue specimens. There was no association between PARP expression and clinical variables. Conclusions In this pilot study, we showed for the first time, that PARP is overexpressed in testicular germ cell tumours compared to normal testis.